Repligen Corp Third Quarter Earnings Sneak Peek
Repligen Corporation (NASDAQ:RGEN) will unveil its latest earnings on Thursday, February 9, 2012. Repligen is a biopharmaceutical company focused primarily on the development of novel therapeutics for radiology and neuropsychiatry.
Repligen Corporation Earnings Preview Cheat Sheet
Wall St. Earnings Expectations: The average estimate of analysts is for a loss of 4 cents per share, a swing from net income of one cent in the year earlier quarter. The average estimate is the same as three months ago. Between one and three months ago, the average estimate was unchanged. It also has not changed during the last month.
Past Earnings Performance: The company topped forecasts last quarter after being in line with estimates the quarter prior. In the second quarter, it reported profit of 2 cents per share versus a mean estimate of 2 cents. Two quarters ago, it reported 0 cents per share.
Investing Insights: Will the iPad 3 Be the Next Catalyst for Apple’s Stock?
Wall St. Revenue Expectations: Analysts are projecting a decline of 1% in revenue from the year-earlier quarter to $7 million.
A Look Back: In the second quarter, profit fell 3% to $604,673 (2 cents a share) from $623,209 (2 cents a share) the year earlier, but exceeded analyst expectations. Revenue rose 18.1% to $8.6 million from $7.3 million.
Revenue has risen the past four quarters. Revenue rose 9.2% in the first quarter from the year earlier, climbed 21.2% in the fourth quarter of the last fiscal year from the year-ago quarter and 25.8% in the third quarter of the last fiscal year.
Repligen’s profit last quarter followed losses in the previous two quarters. The company reported a loss of $55,597 in the first quarter and a loss of $2 million in the fourth quarter of the last fiscal year.
Stock Price Performance: During December 6, 2011 to February 3, 2012, the stock price had risen 87 cents (26.6%) from $3.27 to $4.14. The stock price saw one of its best stretches over the last year between December 15, 2011 and December 23, 2011 when shares rose for seven-straight days, rising 9% (+29 cents) over that span. It saw one of its worst periods between July 26, 2011 and August 3, 2011 when shares fell for seven-straight days, falling 9.3% (-35 cents) over that span.
(Company fundamentals by Xignite Financials. Earnings estimates provided by Zacks)
Don’t Miss These Additional Hot Stories:
To contact the reporter on this story: Derek Hoffman at firstname.lastname@example.org
To contact the editor responsible for this story: Damien Hoffman at email@example.com